Maintenance therapy with Xpovio may extend PFS in some endometrial cancers

UNC Lineberger awarded endometrial cancer SPORE grant

NCI has awarded a five-year, $11.2 million Cancer Health Disparities Specialized Program of Research Excellence in Endometrial Cancer grant to Victoria Bae-Jump and Hazel Nichols at the University of North Carolina Lineberger Comprehensive Cancer Center.

October 10, 2025

Vol.51 No.37

In Brief

UNM’s Kimberly Leslie awarded $12.9M NCI grant to study endometrial cancer

Kimberly Leslie, a professor at the University of New Mexico Comprehensive Cancer Center, was awarded a 5-year, $12.9 million grant from NCI. Leslie and her research team, which includes scientists from the Universities of Iowa, Utah, Kansas, Virginia, and California at San Diego, will study all available hormonal regimens to prevent and treat endometrial cancer.

September 26, 2025

Vol.51 No.35

Drugs & Targets

FDA grants breakthrough designation for Rina-S in advanced endometrial cancer

The FDA has granted Breakthrough Therapy Designation to rinatabart sesutecan (Rina-S), an investigational folate receptor alpha-directed, TOPO1-inhibitor antibody-drug conjugate, for the treatment of adult patients with recurrent or progressive endometrial cancer who have disease progression on or following prior treatment with a platinum-containing regimen and a PD-(L)1 therapy.

September 05, 2025

Vol.51 No.32

In Brief

NCI funds $11.6M “Route 66” SPORE in endometrial cancer

NCI has awarded researchers at Washington University School of Medicine in St. Louis a Specialized Programs of Research Excellence grant to spur new strategies to prevent and treat endometrial cancer.

October 04, 2024

Vol.50 No.37

Clinical Roundup

Data from phase I/II study shows Rina-S improves ORR for treatment of ovarian cancer

Data from the phase I/II study of Rina-S (rinatabart sesutecan), an investigational folate receptor-alpha-targeted, Topo1 antibody-drug conjugate, demonstrated a confirmed objective response rate of 50.0% (95% CI) in ovarian cancer patients treated with Rina-S 120 mg/m2 once every three weeks, regardless of FRα expression levels.

September 20, 2024

Vol.50 No.35